Deborah L. Dunsire's most recent trade in Mckesson Corporation was a trade of 301 Restricted Stock Units (RSUs) done . Disclosure was reported to the exchange on July 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| McKesson | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2025 | 301 | 301 | - | - | Restricted Stock Units (RSUs) | |
| Ultragenyx Pharmaceutical ... | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 10,787 | 10,787 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 5,740 | 30,815 (0%) | 0% | 0 | Common Stock | |
| McKesson | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2024 | 349 | 349 | - | - | Restricted Stock Units (RSUs) | |
| Ultragenyx Pharmaceutical ... | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 9,900 | 9,900 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 5,345 | 25,075 (0%) | 0% | 0 | Common Stock | |
| Syros Pharmaceuticals Inc. | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc. | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 4,000 | 4,000 | - | - | Restricted Stock Units | |
| McKesson | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2024 | 56 | 56 | - | - | Restricted Stock Units (RSUs) | |
| Syros Pharmaceuticals Inc. | Deborah L. Dunsire | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,000 | 0 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Deborah L. Dunsire | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2024 | 4,000 | 12,000 (0%) | 0% | - | Common Stock | |
| Ultragenyx Pharmaceutical ... | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 7,110 | 7,110 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 3,860 | 19,730 (0%) | 0% | 0 | Common Stock | |
| Syros Pharmaceuticals Inc. | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc. | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 4,000 | 4,000 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc. | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Sep 2022 | 8,000 | 8,000 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 6,245 | 6,245 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 3,300 | 15,870 (0%) | 0% | 0 | Common Stock | |
| Syros Pharmaceuticals Inc. | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Ultragenyx Pharmaceutical ... | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 4,125 | 4,125 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Deborah L. Dunsire | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 2,145 | 12,570 (0%) | 0% | 0 | Common stock |